Caribou Biosciences, Inc. · NASDAQ:CRBU
Caribou Biosciences — Corporate Update (July 2023)
36 slides from Caribou Biosciences's corporate update, Jul 13, 2023
Slide 1: CB-010 clinical program update
July 13, 2023 CB-010 clinical program update Transformative genome-edited therapies for patients
Slide 2: Forward-looking statements
Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements speak only as of the date of this presentation and a
Slide 3: The future of CAR-T cell therapies is off-the-shelf
The future of CAR-T cell therapies is off-the-shelf ANTLER dose escalation data Rachel Haurwitz, PhD President & CEO Caribou Biosciences, Inc.
Slide 4: Today's guest
Today’s guest Loretta J. Nastoupil, MD Deputy chair and associate professor in the department of lymphoma/myeloma The University of Texas MD Anderson Cancer Center CB-010 clinical program update | July 2023 4 ©2023 Caribou Biosciences, Inc.
Slide 5: With gratitude for patients, caregivers, investigators
With gratitude for patients, caregivers, investigators • University of Texas MD Anderson Cancer Center • Chao Family Comprehensive Cancer Center / University of California Irvine, Orange T H A N K YO U • Oncology Hematology Care, Cincinnati for your contributions • Baylor Charles A. Sammons Cancer C
Slide 6: CB-010 dose escalation data rival approved autologous CAR-T cell therapies
CB-010 dose escalation data rival approved autologous CAR-T cell therapies 94% overall response rate 69% 44% complete response (CR) rate complete response (CR) (ORR)1 rate2 ≥6 months3 16 1 1 1 dose per patient, dose escalation lymphodepletion regimen 3 dose levels evaluated, patients evaluated all g
Slide 7: CB-010 drives durable CRs that rival autologous CAR-T cell therapies
CB-010 drives durable CRs that rival autologous CAR-T cell therapies 94% 72% 73% 69% CB-010 CR rate at ≥6 months 54% 50% 51% 44% 36% 35% 32% 30% Overall response rate (ORR) Complete response (CR) rate CR rate at 6 months CB-010 Kymriah Yescarta Breyanzi Phase 1 trial Phase 2 trial Phase 1/2 trial Ph
Slide 8: Patients shouldn't have to wait for treatment
Patients shouldn’t have to wait for treatment Allogeneic therapy N=many per batch The future of cell therapy Screening Product is off-the-shelf shipment Days Lymphodepletion Autologous therapy Sample Manufacturing, N=1 shipment product failure identification Queuing, Product Screening leukapheresis
Slide 9: Pipeline: allogeneic cell therapies targeting oncology indications
Pipeline: allogeneic cell therapies targeting oncology indications IND Program Clinical trial Target Indication Discovery Phase 1 Phase 2 Phase 31 Designations enabling CAR-T platform with cell therapies for hematologic indications RMAT, ANTLER CB-010 CD19 r/r B-NHL Fast Track, dose expansion Orphan
Slide 10: CB-010 has a PD-1 KO designed to reduce T cell exhaustion
CB-010 has a PD-1 KO designed to reduce T cell exhaustion Conventional allogeneic CB-010 Key attributes CB-010 anti-CD19 CAR-Ts PD-1 KO Cas9 chRDNA editing for enhanced genomic integrity Anti-CD19 3 TCR KO CAR • Reduced off-target editing and genomic 2 PD-L1 rearrangements 1 CD19 1 TRAC gene knockou
Slide 11: ANTLER Phase 1 trial dose escalation data CB-010
ANTLER Phase 1 trial dose escalation data CB-010 Loretta J. Nastoupil, MD Deputy chair and associate professor in the department of lymphoma/myeloma The University of Texas MD Anderson Cancer Center
Slide 12: Disclosures
Disclosures • LJN has received honorarium for participation in advisory boards or consulting from Abbvie, ADC Therapeutics, Astra Zeneca, BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech/Roche, Genmab, Gilead/Kite, Incyte, Janssen, MorphoSys, Novartis, Regeneron, Sirpant, and Takeda. • L
Slide 13: CB-010 ANTLER Phase 1 trial: dose expansion in 2L LBCL underway
CB-010 ANTLER Phase 1 trial: dose expansion in 2L LBCL underway Part A: 3+3 dose escalation – completed (N=16) Part B: dose expansion – enrolling • Eligibility: aggressive r/r B-NHL1 with ≥2 prior lines of • Eligibility: 2nd line LBCL2 chemoimmunotherapy or primary refractory • Exclusion: prior CD19
Slide 14: Patients in ANTLER all had aggressive r/r B-NHL
Patients in ANTLER all had aggressive r/r B-NHL Patients’ baseline and disease characteristics Characteristics Total (N=16) Median age, years (range) 66 (55-82) Male, n (%) 14 (88) ECOG performance status, n (%) 0 6 (38) 1 10 (62) Time since first diagnosis, years Median (range) 2.4 (0.2-16.4) Non-H
Slide 15: CB-010 has generally well-tolerated safety profile
CB-010 has generally well-tolerated safety profile No DLTs at dose level 2 or dose level 3, no Grade 3+ CRS, no GvHD observed (N=16) AEs of special ANTLER dose escalation (N=16) interest CRS ICANS Infections CRS ICANS1 Infections2, 3 Gr 3+ Gr 3+ Gr 3+ Any grade, N (%) 7 (44%) 4 (25%) 7 (44%) CB-010
Slide 16: CB-010 ANTLER dose escalation efficacy assessment
CB-010 ANTLER dose escalation efficacy assessment Overall depth and duration of response SINGLE CB-010 6-month Prior Best DOSE benchmark Subtype Dose # Rx Resp. Pt # FL1 40M 8 CR 1 DLBCL 40M 4 CR 4 DLBCL2 80M 1 CR 7 CR: complete response DLBCL2 80M 1 CR 8 PR: partial response PMBCL3 40M 2 CR 5 SD: s
Slide 17: Subgroup efficacy profile supports 2L LBCL clinical development
Subgroup efficacy profile supports 2L LBCL clinical development r/r B-NHL r/r LBCL2 2L LBCL3 Endpoints All patients Subgroup Subgroup N, (%) (N=16) (N=10) (N=4) Overall response rate (ORR)1 15 (94%) 9 (90%) 4 (100%) Complete response (CR) rate1 11 (69%) 7 (70%) 2 (50%) ≥6-month CR rate1 7 (44%) 5 (5
Slide 18: Fireside chat
Fireside chat CARIBOU Pm BIOSCIENCES’
Slide 19: Fireside chat with Dr. Nastoupil
Fireside chat with Dr. Nastoupil Loretta J. Nastoupil, MD Rachel Haurwitz, PhD Deputy chair and associate professor in the President and CEO department of lymphoma/myeloma Caribou Biosciences The University of Texas MD Anderson Cancer Center CB-010 clinical program update | July 2023 19 ©2023 Caribo
Slide 20: Q&A
Q&A CARIBOU Pm BIOSCIENCES’
Slide 21: Open to your questions
Open to your questions Rachel Haurwitz, PhD Syed Rizvi, MD President and CEO CMO Loretta J. Nastoupil, MD Deputy chair and associate professor in the department of lymphoma/myeloma The University of Texas MD Anderson Cancer Center Steve Kanner, PhD CSO Caribou Biosciences CB-010 clinical program upd
Slide 22: Closing remarks
Closing remarks Rachel Haurwitz, PhD President & CEO Caribou Biosciences, Inc.
Slide 23: With gratitude for patients, caregivers, investigators
With gratitude for patients, caregivers, investigators • University of Texas MD Anderson Cancer Center • Chao Family Comprehensive Cancer Center / University of California Irvine, Orange T H A N K YO U • Oncology Hematology Care, Cincinnati for your contributions • Baylor Charles A. Sammons Cancer C
Slide 24: Dose escalation data support ANTLER dose expansion
Dose escalation data support ANTLER dose expansion CB-010 single dose allogeneic CAR-T cell therapy 94% overall response rate (ORR)1 ➢ Response rates rival approved autologous CAR-T cell therapies ➢ Generally well-tolerated safety profile 69% complete response (CR) ➢ Off-the-shelf, readily-available
Slide 25: The momentum continues in 2023
The momentum continues in 2023 Recent accomplishments CB-010 CB-011 CB-012 Well capitalized Positive dose escalation data CaMMouflage trial initiated Presented $292.5M in cash1 Enrolling 2L LBCL patients in First patient dosed AACR poster with Expected runway into dose expansion Fast Track designati
Slide 26: Thank you
Thank you https://cariboubio.com info@cariboubio.com
Slide 27: Appendix
Appendix CARIBOU Pm BIOSCIENCES’
Slide 28: Potential to address high unmet medical need in 2L LBCL
Potential to address high unmet medical need in 2L LBCL LBCL patient treatment journey (U.S. incidence 2022) tCLL tFL 3% Diagnosed ~32.4K patients 5% DLBCL PMBCL 11% 1L ~30.8K patients HGBL 10% ~32.4K patients 71% CB-010 ANTLER 2L ~10.0K patients dose expansion 3L ~4.4K patients CB-010 clinical prog
Slide 29: CB-010 ANTLER dose escalation efficacy assessment
CB-010 ANTLER dose escalation efficacy assessment Overall, r/r, and 2L LBCL subgroups, by dose level r/r B-NHL r/r LBCL2 2L LBCL3 CB-010 dose level Endpoints All patients Subgroup Subgroup 40M 80M 120M (N, %) (N=16) (N=10) (N=4) (N=8) (N=5) (N=3) Overall response rate 15 (94%) 9 (90%) 4 (100%) 8 (10
Slide 30: CB-010's responses rival autologous CAR-T cell therapies
CB-010’s responses rival autologous CAR-T cell therapies CB-010 Kymriah Yescarta Breyanzi dose escalation Phase 2 Phase 1/2 Phase 1 Phase 1 % (n/N) % (n/N) % (n/N2) % (n/N) Overall response rate (ORR)1 94% (15/16) 50% (34/68) 72% (73/101) 73% (141/192) Complete response (CR) rate1 69% (11/16) 32% (2
Slide 31: CB-010 is generally well tolerated
CB-010 is generally well tolerated Treatment-emergent adverse events (TEAE) Event Any Grade1 All Grade 3+ Related Grade 3+ (N=16) N (%) N (%) N (%) Total number of TEAEs, N 348 96 28 Subjects with TEAE, n (%) 15 (94) 14 (88) 8 (50) Thrombocytopenia/platelet count decreased 11 (69) 11 (69) 5 (31) Ane
Slide 32: CB-010 demonstrated differentiated, long-term antitumor activity in preclinical studies
CB-010 demonstrated differentiated, long-term antitumor activity in preclinical studies A single dose of CB-010 resulted in profound tumor regression of metastatic CD19+ tumor xenografts and led to a significantly longer antitumor response and survival vs. conventional CD19-specific allogeneic CAR-T
Slide 33: Allogeneic CAR-T cell manufacturing process overview for CB-010
Allogeneic CAR-T cell manufacturing process overview for CB-010 Caribou’s process development team created the manufacturing process and transferred it to a CMO to generate phase 1 cGMP clinical material cGMP starting Genetic modification via Gene-modified In vitro expansion of Removal of residual F
Slide 34: Caribou is a leader in the allogeneic CAR-T cell space
Caribou is a leader in the allogeneic CAR-T cell space with a platform of genome-edited cell therapies 3 Edits 4 Edits 5 Edits B2M–HLA-E PD-1 KO B2M–HLA-E PD-1 KO CB-010 CB-011 CB-012 Anti-CD19 Anti-BCMA Anti-CLL-1 B cell non-Hodgkin Multiple Acute myeloid lymphoma CAR myeloma CAR leukemia CAR TCR K
Slide 35: Caribou's technologies offer broad applications to enable transformational therapies
Caribou’s technologies offer broad applications to enable transformational therapies Initial focus on allogeneic cell therapies with: Potential for improved Enhanced antitumor activity through Checkpoint Immune cytotoxic diverse genome-editing disruption cloaking activity strategies Future potential
Slide 36: Experienced management team
Experienced management team Rachel Steve Jason Syed Barbara Ruhi Haurwitz, PhD Kanner, PhD O’Byrne Rizvi, MD McClung, JD Khan President and CEO Chief scientific officer Chief financial officer Chief medical officer Chief legal officer and Chief business officer Director corporate secretary CB-010 cl